{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:50:39Z","timestamp":1785333039408,"version":"3.55.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001030","name":"National Heart Foundation of Australia","doi-asserted-by":"publisher","award":["104814"],"award-info":[{"award-number":["104814"]}],"id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001030","name":"National Heart Foundation of Australia","doi-asserted-by":"publisher","award":["106025"],"award-info":[{"award-number":["106025"]}],"id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010635","name":"Hunter New England Local Health District","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010635","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100025520","name":"Medical Research Future Fund","doi-asserted-by":"publisher","award":["MRF2017053"],"award-info":[{"award-number":["MRF2017053"]}],"id":[{"id":"10.13039\/501100025520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","award":["2023\/ARIG1009"],"award-info":[{"award-number":["2023\/ARIG1009"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001516","name":"National Heart Foundation of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001516","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008810","name":"New South Wales Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008810","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009287","name":"NSW Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Australian Government Department of Health Disability and Ageing","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.tcm.2025.10.008","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T01:34:38Z","timestamp":1761356078000},"page":"218-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cardiometabolic perturbations arising from treatment with novel anticancer therapies"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8704-752X","authenticated-orcid":false,"given":"Joshua D","family":"Bennetts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2539-8038","authenticated-orcid":false,"given":"Aaron L","family":"Sverdlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doan TM","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.tcm.2025.10.008_bib0001","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/cancers12030731","article-title":"Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy","volume":"12","author":"Pottier","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tcm.2025.10.008_bib0002","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2019.04.035","article-title":"The evolving landscape of \u2018next-generation\u2019immune checkpoint inhibitors: a review","volume":"117","author":"Mazzarella","year":"2019","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.tcm.2025.10.008_bib0003","first-page":"36","article-title":"Navigating the crossroads: cardiometabolic risks in cancer survivorship - a comprehensive review","volume":"10","author":"Albulushi","year":"2024","journal-title":"Cardiooncology"},{"key":"10.1016\/j.tcm.2025.10.008_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.ando.2018.07.005","article-title":"Endocrine side-effects of new anticancer therapies: overall monitoring and conclusions","author":"Castinetti","year":"2018","journal-title":"Ann endocrinol;"},{"issue":"9","key":"10.1016\/j.tcm.2025.10.008_bib0005","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41569-024-01017-x","article-title":"Cardiovascular disease and cancer: shared risk factors and mechanisms","volume":"21","author":"Wilcox","year":"2024","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"10.1016\/j.tcm.2025.10.008_bib0006","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024735","article-title":"Underdiagnosis and undertreatment of modifiable cardiovascular risk factors among survivors of childhood cancer","volume":"11","author":"Chow","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.tcm.2025.10.008_bib0007","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1007\/s11764-023-01347-8","article-title":"Prevalence of health behaviors among cancer survivors in the United States","volume":"18","author":"Gregory","year":"2024","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.tcm.2025.10.008_bib0008","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.metabol.2017.09.013","article-title":"Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes","volume":"78","author":"Gallo","year":"2018","journal-title":"Metabolism"},{"issue":"22","key":"10.1016\/j.tcm.2025.10.008_bib0009","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.3390\/cancers13225735","article-title":"Diabetes and cancer: risk, challenges, management and outcomes","volume":"13","author":"Shahid","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.tcm.2025.10.008_bib0010","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12933-018-0762-4","article-title":"Association between insulin resistance and the development of cardiovascular disease","volume":"17","author":"Ormazabal","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.tcm.2025.10.008_bib0011","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1677\/ERC-09-0087","article-title":"Diabetes and cancer","volume":"16","author":"Vigneri","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"01","key":"10.1016\/j.tcm.2025.10.008_bib0012","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1055\/s-0029-1243193","article-title":"Diabetes mellitus type 2\u2013an independent risk factor for cancer?","volume":"118","author":"Grote","year":"2010","journal-title":"Exp clin endocrinol diabetes"},{"issue":"9","key":"10.1016\/j.tcm.2025.10.008_bib0013","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s00125-010-1796-7","article-title":"Diabetes, prediabetes and cancer mortality","volume":"53","author":"Zhou","year":"2010","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.tcm.2025.10.008_bib0014","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00125-014-3186-z","article-title":"Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment","volume":"57","author":"Ranc","year":"2014","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.tcm.2025.10.008_bib0015","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1152\/physrev.00030.2014","article-title":"Obesity and diabetes: the increased risk of cancer and cancer-related mortality","volume":"95","author":"Gallagher","year":"2015","journal-title":"Physiol Rev"},{"issue":"7","key":"10.1016\/j.tcm.2025.10.008_bib0016","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djp025","article-title":"Glucose intolerance during adjuvant chemotherapy for breast cancer","volume":"101","author":"Hickish","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.tcm.2025.10.008_bib0017","first-page":"9431","article-title":"High burden of diabetes and prediabetes among cancer patients at University of Gondar comprehensive specialized hospital","volume":"13","author":"Wolde","year":"2023","journal-title":"Northwest Ethiop Sci Rep"},{"issue":"8","key":"10.1016\/j.tcm.2025.10.008_bib0018","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamaoncol.2018.1684","article-title":"Incidence of diabetes after cancer development: a Korean national cohort study","volume":"4","author":"Hwangbo","year":"2018","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.tcm.2025.10.008_bib0019","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.4239\/wjd.v12.i7.1010","article-title":"Current cancer therapies and their influence on glucose control","volume":"12","author":"Yim","year":"2021","journal-title":"World J Diabetes"},{"key":"10.1016\/j.tcm.2025.10.008_bib0020","author":"Silvestris","year":"2020","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"1","key":"10.1016\/j.tcm.2025.10.008_bib0021","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41572-020-0165-1","article-title":"Diabetic ketoacidosis","volume":"6","author":"Dhatariya","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.tcm.2025.10.008_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-020-0165-1","article-title":"Diabetic ketoacidosis","volume":"6","author":"Dhatariya","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"10.1016\/j.tcm.2025.10.008_bib0023","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40618-018-0984-z","article-title":"Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know)","volume":"42","author":"Ruggeri","year":"2019","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"10.1016\/j.tcm.2025.10.008_bib0024","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/cei.13424","article-title":"Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes","volume":"200","author":"Quandt","year":"2020","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.tcm.2025.10.008_bib0025","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1634\/theoncologist.2018-0470","article-title":"Endocrine-related adverse events related to immune checkpoint inhibitors: proposed algorithms for management","volume":"25","author":"Del Rivero","year":"2020","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.tcm.2025.10.008_bib0026","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.tcm.2025.10.008_bib0027","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s00262-023-03436-0","article-title":"Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients","volume":"72","author":"\u00d6zdemir","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.tcm.2025.10.008_bib0028","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.tcm.2025.10.008_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108633","article-title":"Characterization of hyperglycemia in patients receiving immune checkpoint inhibitors: beyond autoimmune insulin-dependent diabetes","volume":"172","author":"Leiter","year":"2021","journal-title":"Diabetes Res Clin Pr"},{"issue":"11","key":"10.1016\/j.tcm.2025.10.008_bib0030","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1634\/theoncologist.2015-0519","article-title":"Hyperglycemia associated with targeted oncologic treatment: mechanisms and management","volume":"21","author":"Goldman","year":"2016","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.tcm.2025.10.008_bib0031","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2337\/dc21-2213","article-title":"Immune checkpoint inhibitors and risk of type 1 diabetes","volume":"45","author":"Chen","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.tcm.2025.10.008_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.tcm.2025.10.008_bib0033","article-title":"Cardiometabolic consequences of targeted anticancer therapies","author":"Guha","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"issue":"10","key":"10.1016\/j.tcm.2025.10.008_bib0034","doi-asserted-by":"crossref","first-page":"E342","DOI":"10.1002\/ajh.25232","article-title":"Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy","volume":"93","author":"Racil","year":"2018","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.tcm.2025.10.008_bib0035","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.blre.2018.01.004","article-title":"Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: strategies for monitoring, detecting, and managing","volume":"32","author":"Medeiros","year":"2018","journal-title":"Blood Rev"},{"issue":"3","key":"10.1016\/j.tcm.2025.10.008_bib0036","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40264-016-0485-y","article-title":"Hyperglycaemia induced by novel anticancer agents: an undesirable complication or a potential therapeutic opportunity?","volume":"40","author":"Shah","year":"2017","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.tcm.2025.10.008_bib0037","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrm.2017.89","article-title":"Biochemical and cellular properties of insulin receptor signalling","volume":"19","author":"Haeusler","year":"2018","journal-title":"Nat rev Mol cell biol"},{"issue":"10226","key":"10.1016\/j.tcm.2025.10.008_bib0038","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(19)32008-2","article-title":"Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study","volume":"395","author":"Yusuf","year":"2020","journal-title":"Lancet"},{"issue":"48","key":"10.1016\/j.tcm.2025.10.008_bib0039","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis","volume":"42","author":"Dolladille","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2025.10.008_bib0040","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2019.06.021","article-title":"Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study","volume":"120","author":"Bar","year":"2019","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.tcm.2025.10.008_bib0041","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1080\/21645515.2020.1852872","article-title":"The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the \u201cinflamed tumor\u201d to the \u201cinflamed patient","volume":"17","author":"Bersanelli","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.tcm.2025.10.008_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.carpath.2019.107148","article-title":"Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis","volume":"43","author":"Newman","year":"2019","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.tcm.2025.10.008_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.ando.2018.07.011","article-title":"Expert opinion on the metabolic complications of new anticancer therapies: tyrosine kinase inhibitors","author":"Buffier","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"issue":"7","key":"10.1016\/j.tcm.2025.10.008_bib0044","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3324\/haematol.2014.104075","article-title":"Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia","volume":"99","author":"Rea","year":"2014","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.tcm.2025.10.008_bib0045","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/ajco.12473","article-title":"A study on the association between hyperlipidemia and hypothyroidism and the response to TKIs in metastatic renal cell carcinoma","volume":"12","author":"Song","year":"2016","journal-title":"Asia Pac J Clin Oncol"},{"issue":"5","key":"10.1016\/j.tcm.2025.10.008_bib0046","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.3390\/jcm9051268","article-title":"Cardiovascular complications of systemic therapy in non-small-cell lung cancer","volume":"9","author":"Zaborowska-Szmit","year":"2020","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.tcm.2025.10.008_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2015.07.001","article-title":"Long-term safety with axitinib in previously treated patients with metastatic renal cell carcinoma","volume":"13","author":"Rini","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.tcm.2025.10.008_bib0048","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.vph.2017.10.004","article-title":"Axitinib attenuates intraplaque angiogenesis, haemorrhages and plaque destabilization in mice","volume":"100","author":"Van der Veken","year":"2018","journal-title":"Vasc Pharmacol"},{"issue":"9","key":"10.1016\/j.tcm.2025.10.008_bib0049","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"lancet oncol"},{"key":"10.1016\/j.tcm.2025.10.008_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175869","article-title":"Tyrosine kinase inhibitors and atherosclerosis: a close but complicated relationship","volume":"954","author":"Xu","year":"2023","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"10.1016\/j.tcm.2025.10.008_bib0051","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/s41375-018-0337-0","article-title":"Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts","volume":"33","author":"Sadiq","year":"2019","journal-title":"leukemia"},{"issue":"4","key":"10.1016\/j.tcm.2025.10.008_bib0052","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11154-018-9463-2","article-title":"Thyroid disorders induced by checkpoint inhibitors","volume":"19","author":"Ferrari","year":"2018","journal-title":"Rev Endocr Metab Disord"},{"issue":"03","key":"10.1016\/j.tcm.2025.10.008_bib0053","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"Velkeniers B. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"De Filette","year":"2019","journal-title":"Horm Metab Res"},{"issue":"10","key":"10.1016\/j.tcm.2025.10.008_bib0054","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s40618-020-01226-4","article-title":"Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study","volume":"43","author":"Bai","year":"2020","journal-title":"J Endocrinol Invest"},{"issue":"230","key":"10.1016\/j.tcm.2025.10.008_bib0055","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.tcm.2025.10.008_bib0056","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.tcm.2025.10.008_bib0057","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","author":"de Filette","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.tcm.2025.10.008_bib0058","first-page":"32","article-title":"Anticancer drug-induced thyroid dysfunction","volume":"16","author":"Bhattacharya","year":"2020","journal-title":"Eur Endocrinol"},{"issue":"4","key":"10.1016\/j.tcm.2025.10.008_bib0059","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3109\/0284186X.2012.752579","article-title":"Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis","volume":"52","author":"Funakoshi","year":"2013","journal-title":"Acta Oncol (Madr)"},{"issue":"4","key":"10.1016\/j.tcm.2025.10.008_bib0060","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/03602532.2019.1687512","article-title":"Current evidence on thyroid related adverse events in patients treated with protein tyrosine kinase inhibitors","volume":"51","author":"Gabora","year":"2019","journal-title":"Drug Metab Rev"},{"issue":"1","key":"10.1016\/j.tcm.2025.10.008_bib0061","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1530\/EJE-20-0683","article-title":"Therapy of Endocrine Disease: endocrine-metabolic effects of treatment with multikinase inhibitors","volume":"184","author":"Fallahi","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.tcm.2025.10.008_bib0062","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3390\/cancers14030593","article-title":"Endocrine toxicities of antineoplastic therapy: the adrenal topic","volume":"14","author":"Barnabei","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tcm.2025.10.008_bib0063","article-title":"Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism","author":"Basolo","year":"2021","journal-title":"Semin Cancer Biol;"},{"issue":"9","key":"10.1016\/j.tcm.2025.10.008_bib0064","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-018-0718-6","article-title":"Immune checkpoint inhibitor toxicity","volume":"20","author":"Palmieri","year":"2018","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"10.1016\/j.tcm.2025.10.008_bib0065","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor\u2013Induced type 1 diabetes mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.tcm.2025.10.008_bib0066","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.tcm.2025.10.008_bib0067","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1089\/thy.2010.0251","article-title":"Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia","volume":"20","author":"Kim","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.tcm.2025.10.008_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102969","article-title":"A user\u2019s guide to lorlatinib","volume":"151","author":"Nagasaka","year":"2020","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"6","key":"10.1016\/j.tcm.2025.10.008_bib0069","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1007\/s12325-020-01365-3","article-title":"Consensus recommendations for management and counseling of adverse events associated with Lorlatinib: a guide for healthcare practitioners","volume":"37","author":"Reed","year":"2020","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.tcm.2025.10.008_bib0070","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/03007995.2017.1399870","article-title":"Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US","volume":"34","author":"Franklin","year":"2018","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"10.1016\/j.tcm.2025.10.008_bib0071","first-page":"531","article-title":"Cardiovascular events and atherogenic lipid profile in chronic myeloid leukemia patients treated with nilotinib versus imatinib","volume":"122","author":"Petrikova","year":"2021","journal-title":"Bratisl Lek Listy"},{"issue":"4","key":"10.1016\/j.tcm.2025.10.008_bib0072","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/thy.2017.0579","article-title":"Risk factors for new hypothyroidism during tyrosine kinase inhibitor therapy in advanced nonthyroidal cancer patients","volume":"28","author":"Lechner","year":"2018","journal-title":"Thyroid"},{"issue":"24","key":"10.1016\/j.tcm.2025.10.008_bib0073","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.tcm.2025.10.008_bib0074","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaccao.2022.11.011","article-title":"Atherosclerosis with Immune checkpoint inhibitor therapy: evidence, diagnosis, and management: JACC: CardioOncology State-of-the-art review","volume":"4","author":"Suero-Abreu","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"36","key":"10.1016\/j.tcm.2025.10.008_bib0075","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.tcm.2025.10.008_bib0076","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14636","article-title":"Joint British Diabetes Society for Inpatient Care UCB. A guideline for the outpatient management of glycaemic control in people with cancer","volume":"39","author":"Joharatnam-Hogan","year":"2022","journal-title":"Diabet Med"},{"issue":"9","key":"10.1016\/j.tcm.2025.10.008_bib0077","doi-asserted-by":"crossref","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid immune-related adverse events following Immune checkpoint inhibitor treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.tcm.2025.10.008_bib0078","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.tcm.2025.10.008_bib0079","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with Immune checkpoint inhibitor therapy: american Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.tcm.2025.10.008_bib0080","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"10.1016\/j.tcm.2025.10.008_bib0081","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3390\/jcm9082664","article-title":"Factors associated with adverse cardiovascular events in cancer patients treated with bevacizumab","volume":"9","author":"Ngo","year":"2020","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.tcm.2025.10.008_bib0082","first-page":"312","article-title":"Suboptimal use of cardioprotective medications in patients with a history of cancer","volume":"2","author":"Untaru","year":"2020","journal-title":"JACC: CardioOncology"},{"issue":"22","key":"10.1016\/j.tcm.2025.10.008_bib0083","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1200\/JCO.22.00687","article-title":"Exercise, diet, and weight management during cancer treatment: ASCO guideline","volume":"40","author":"Ligibel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.tcm.2025.10.008_bib0084","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EC-18-0068","article-title":"SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: acute management of the endocrine complications of checkpoint inhibitor therapy","volume":"7","author":"Higham","year":"2018","journal-title":"Endocr Connect"},{"issue":"1","key":"10.1016\/j.tcm.2025.10.008_bib0085","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/curroncol28010029","article-title":"Evaluation and management of dyslipidemia in patients treated with Lorlatinib","volume":"28","author":"Blais","year":"2021","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.tcm.2025.10.008_bib0086","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ando.2023.03.009","article-title":"Endocrine-related adverse conditions induced by tyrosine kinase inhibitors","volume":"84","author":"De Leo","year":"2023","journal-title":"Ann Endocrinol (Paris)"},{"issue":"7","key":"10.1016\/j.tcm.2025.10.008_bib0087","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/archinte.168.7.687","article-title":"Pharmacist care of patients with heart failure: a systematic review of randomized trials","volume":"168","author":"Koshman","year":"2008","journal-title":"Arch Intern Med"},{"issue":"12","key":"10.1016\/j.tcm.2025.10.008_bib0088","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.2337\/dc12-0369","article-title":"Pharmacist interventions to improve cardiovascular disease risk factors in diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"35","author":"Santschi","year":"2012","journal-title":"Diabetes care"},{"issue":"5","key":"10.1016\/j.tcm.2025.10.008_bib0089","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-082228","article-title":"Pharmacist-led medication management services: a qualitative exploration of transition-of-care cardiovascular disease patient experiences","volume":"14","author":"Bennetts","year":"2024","journal-title":"BMJ open"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173825001422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173825001422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:43:11Z","timestamp":1778758991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173825001422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":89,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1050173825001422"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2025.10.008","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiometabolic perturbations arising from treatment with novel anticancer therapies","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2025.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}